| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Florian Herse | Q47804678 |
| P2093 | author name string | Babbette LaMarca | |
| P2860 | cites work | Fetal origins of cardiovascular disease. | Q33643876 |
| Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia | Q33748650 | ||
| Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity | Q33748680 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Pathogenesis and genetics of pre-eclampsia | Q33934445 | ||
| ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. | Q33990220 | ||
| Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia | Q34040357 | ||
| Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy | Q34182166 | ||
| A study of angiotensin II pressor response throughout primigravid pregnancy | Q34512573 | ||
| Recent Insights into the pathogenesis of pre-eclampsia | Q34682287 | ||
| Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes | Q35029700 | ||
| Pre-eclampsia, the placenta and the maternal systemic inflammatory response--a review | Q35169648 | ||
| Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction | Q35576417 | ||
| Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 | ||
| Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia | Q35681821 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia | Q35793389 | ||
| Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats | Q35994304 | ||
| Preeclampsia: recent insights | Q36288757 | ||
| The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy | Q36407259 | ||
| The role of RAS in the pathogenesis of preeclampsia | Q36467563 | ||
| Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa | Q36515453 | ||
| Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats | Q36683260 | ||
| Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats | Q37436219 | ||
| Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. | Q37447371 | ||
| Novel insights on the role of the innate immune system in systemic sclerosis. | Q37905792 | ||
| Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies | Q38494999 | ||
| Intrauterine programming of coronary heart disease and stroke | Q41663229 | ||
| Hypertensive disorders in pregnancy | Q43530362 | ||
| Placental superoxide is increased in pre-eclampsia | Q43564655 | ||
| Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. | Q43576536 | ||
| Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation | Q44302005 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 | ||
| Teratogenicity with angiotensin II receptor antagonists in pregnancy | Q46948262 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. | Q51359651 | ||
| Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. | Q52900457 | ||
| Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. | Q52933863 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. | Q54570213 | ||
| Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. | Q54661322 | ||
| Trophoblasts Reduce the Vascular Smooth Muscle Cell Proatherogenic Response | Q56981910 | ||
| Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia | Q56981931 | ||
| CD19 + CD5 + Cells as Indicators of Preeclampsia | Q59906564 | ||
| Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-antagonists | Q61943646 | ||
| Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986 | Q64128968 | ||
| A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies | Q67586423 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension | Q74126541 | ||
| Definitive molecular evidence of renin-angiotensin system in human uterine decidual cells | Q74188076 | ||
| Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women | Q74384559 | ||
| Explaining and predicting preeclampsia | Q80223255 | ||
| Agonistic autoantibodies and rejection of renal allografts | Q81386151 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists | Q82975650 | ||
| Activation of the complement system in normal pregnancy and preeclampsia | Q83021096 | ||
| Decreased expression of complement 3a receptor (C3aR) in human placentas from severe preeclamptic pregnancies | Q84819984 | ||
| P433 | issue | 4 | |
| P921 | main subject | arterial hypertension | Q41861 |
| autoantibody | Q785022 | ||
| maternal health | Q6786626 | ||
| P304 | page(s) | 413-418 | |
| P577 | publication date | 2012-12-28 | |
| P1433 | published in | American Journal of Reproductive Immunology | Q15761228 |
| P1476 | title | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension | |
| P478 | volume | 69 |
| Q35151065 | 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model |
| Q28069689 | A Dormant Microbial Component in the Development of Preeclampsia |
| Q53700889 | AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. |
| Q34541831 | Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor Enhance Angiotensin II-Induced Renal Vascular Sensitivity and Reduce Renal Function During Pregnancy |
| Q38232126 | Applications of cell-based bioassays measuring the induced expression of endogenous genes |
| Q33789436 | B cells: the old new players in reproductive immunology |
| Q36339273 | Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats |
| Q26852668 | Elucidating immune mechanisms causing hypertension during pregnancy |
| Q92504676 | Endogenous Bufadienolides, Fibrosis and Preeclampsia |
| Q35175524 | Exposure to experimental preeclampsia in mice enhances the vascular response to future injury |
| Q38237354 | How does preeclampsia predispose to future cardiovascular disease? |
| Q53433801 | Identification of a Novel Agonist-Like Autoantibody in Preeclamptic Patients. |
| Q37139722 | Identifying immune mechanisms mediating the hypertension during preeclampsia |
| Q36241932 | International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. |
| Q55004295 | Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study. |
| Q46308383 | Microvascular endothelial cells from preeclamptic women exhibit altered expression of angiogenic and vasopressor factors |
| Q55426884 | Modeling Superimposed Preeclampsia Using Ang II (Angiotensin II) Infusion in Pregnant Stroke-Prone Spontaneously Hypertensive Rats. |
| Q39208841 | Pharmacogenetics in the treatment of pre-eclampsia: current findings, challenges and perspectives |
| Q92071244 | Placental CD4+ T cells isolated from preeclamptic women cause preeclampsia-like symptoms in pregnant nude-athymic rats |
| Q64226376 | Placental CX3CL1 is Deregulated by Angiotensin II and Contributes to a Pro-Inflammatory Trophoblast-Monocyte Interaction |
| Q37451544 | Placental Ischemia and Resultant Phenotype in Animal Models of Preeclampsia |
| Q33416340 | Pre-eclampsia part 1: current understanding of its pathophysiology |
| Q38705264 | Preeclampsia As Modulator of Offspring Health |
| Q26800272 | Preeclampsia: long-term consequences for vascular health |
| Q34506462 | Protein profiling of preeclampsia placental tissues |
| Q92071252 | Renal natural killer cell activation and mitochondrial oxidative stress; new mechanisms in AT1-AA mediated hypertensive pregnancy |
| Q45350029 | Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia |
| Q57150158 | The role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia |
| Q33834419 | The role of inflammation in the pathology of preeclampsia |
| Q26994764 | The treatment of hypertension during pregnancy: when should blood pressure medications be started? |
| Q51294484 | Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in preeclampsia including hypertension. |
Search more.